Follow The Filings

ENTA position history

The shares of Enanta Pharmaceuticals (ENTA) that Krensavage Asset Management LLC reported in each quarter’s 13F.

Equity, COM

Shares held by quarter

New Add Reduce Exit

  1. 2021 Q3: 936,777 shares, $53M, 16.7% of portfolio
  2. 2021 Q4: 564,102 shares, $42M, 14.6% of portfolio, Reduce −39.8%
  3. 2022 Q1: 548,828 shares, $39M, 13.5% of portfolio, Reduce −2.7%
  4. 2022 Q2: 624,768 shares, $30M, 9.8% of portfolio, Add +13.8%
  5. 2022 Q3: 589,360 shares, $31M, 9.7% of portfolio, Reduce −5.7%
  6. 2022 Q4: 594,818 shares, $28M, 8.5% of portfolio, Add +0.9%
  7. 2023 Q1: 603,301 shares, $24M, 7.4% of portfolio, Add +1.4%
  8. 2023 Q2: 687,613 shares, $15M, 4.7% of portfolio, Add +14.0%
  9. 2023 Q3: 735,103 shares, $8.2M, 3.0% of portfolio, Add +6.9%
  10. 2023 Q4: 742,824 shares, $7M, 2.5% of portfolio, Add +1.1%
  11. 2024 Q1: 1,124,586 shares, $20M, 8.7% of portfolio, Add +51.4%
  12. 2024 Q2: 1,251,338 shares, $16M, 7.5% of portfolio, Add +11.3%
  13. 2024 Q3: 1,498,074 shares, $16M, 8.7% of portfolio, Add +19.7%
  14. 2024 Q4: 3,615,464 shares, $24M, 14.4% of portfolio, Add +141.3%
  15. 2025 Q1: 2,116,586 shares, $12M, 6.5% of portfolio, Reduce −41.5%
  16. 2025 Q2: 2,114,444 shares, $16M, 8.5% of portfolio, Reduce −0.1%
  17. 2025 Q3: 2,114,444 shares, $25M, 10.8% of portfolio
  18. 2025 Q4: 2,766,390 shares, $44M, 15.4% of portfolio, Add +30.8%
  19. 2026 Q1: 2,866,138 shares, $36M, 14.2% of portfolio, Add +3.6%
  20. 2026 Q2: 2,866,138 shares, $42M, 15.9% of portfolio
  21. 2026 Q3: 2,866,138 shares, $38M, 14.2% of portfolio
Holdings date Value % of holdings Shares Filing date All 13F holders